ASRT Assertio Holdings, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001808665
AI RATING
STRONG_SELL
87% Confidence

Investment Thesis

Assertio is a severely unprofitable pharmaceutical company experiencing deteriorating fundamentals with revenue of $9.9M declining YoY while operating losses exceed $18M, creating a structurally unsustainable business model. Despite $33.7M in cash providing near-term operating runway, the company loses $1.90 on every dollar of revenue with worsening per-share losses, indicating no clear path to profitability without radical transformation.

Strengths

  • + Positive operating and free cash flow of $8.6M despite significant net losses indicates some working capital discipline
  • + Adequate cash position of $33.7M providing 12-18 months of operational runway at current burn rates
  • + Healthy liquidity ratios (1.82x current, 1.57x quick) and moderate leverage (0.52x debt/equity)

Risks

  • ! Catastrophic operating losses of -$18.5M with -185.9% operating margin on $9.9M revenue base
  • ! Revenue declining -5% YoY paired with worsening diluted EPS (-39.4% YoY), indicating structural decline
  • ! Negative returns on equity (-24.9%) and assets (-8.9%) demonstrate value destruction; cash runway insufficient if losses persist

Key Metrics to Watch

Financial Metrics

Revenue
9.9M
Net Income
-18.9M
EPS (Diluted)
$-2.93
Free Cash Flow
8.6M
Total Assets
211.3M
Cash
33.7M

Profitability Ratios

Gross Margin N/A
Operating Margin -185.9%
Net Margin -189.8%
ROE -24.9%
ROA -8.9%
FCF Margin 86.2%

Balance Sheet & Liquidity

Current Ratio
1.82x
Quick Ratio
1.57x
Debt/Equity
0.52x
Debt/Assets
64.2%
Interest Coverage
N/A
Long-term Debt
39.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-13T07:48:34.042131 | Data as of: 2026-03-31 | Powered by Claude AI